Ionis is up ~25%. Explore why Olezarsen, recent approvals, and upcoming catalysts could drive more upside. Click here to read ...
PMI’s FDA-approved SynCardia STAH is promising, but adoption and revenues lag; cash burn and dilution weigh. Read the full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback